Start-Up Elara Formed to Develop Anticancer Drugs
Posted on: Thursday, 10 August 2006, 21:00 CDT
Commercial and venture affiliates of research center the European Molecular Biology Laboratory have formed Elara Pharmaceuticals GmbH, a start-up company to develop anticancer drugs.
Elara is a spinout company dedicated to drug development and will follow up on promising small molecule leads that have shown powerful anticancer actions in screening experiments. Elara will receive seed funding from EMBL Ventures and has been granted exclusive license rights to selected discoveries made at the European Molecular Biology Laboratory (EMBL).
Elara will follow up on promising leads of molecules that block the signaling protein Aurora kinase A, which is strongly overexpressed in cancer cells, and on inhibitors that affect estrogen receptor signaling, a process essential in the development of breast cancer.
"Traditionally, there is a significant gap between basic research and drug development," said Christof Antz, managing director of EMBL Ventures. "It often takes years to get from promising findings to a therapeutic approach. With Elara we aim to bridge this gap and create a direct pipeline from the Laboratory by way of animal testing to clinical development."
Source: Datamonitor
Related Articles
- Lockheed Martin Develops Airborne Laboratory for C4ISR Experimentation
- Tele Atlas Survey Reveals Web Application Developers See Great Promise and Business Opportunity With Location-Based Services
- Curis Announces Presentation at CHI's ''Discovery on Target: Developing Inhibitors for Promising Drug Targets'' Conference
- Northwest Hospital & Medical Center to Develop Sleep Laboratory
- Boston Life Sciences Acquires Rights to Develop and Commercialize Promising Phase II Spinal Cord Injury Drug, Cethrin(R), in Exclusive Worldwide License
- Promising New Antimalarial Drug Demonstrates Significant Parasite Reduction in Patients
- Future Developments in Biopharmaceuticals Promise Innovative and Cost-Effective Therapies
- Future Developments in Biopharmaceuticals Promise Cost-Effective and Innovative Therapies
- Endovasc Outlines Plans for Continued Development of Liprostin; Promising Phase II Clinical Trial Results Warrant Further Trials
- Sequella, Inc. And Sankyo Co., Ltd. Sign Worldwide Licensing Agreement to Develop and Market Promising New Anti-Tuberculosis Compounds
 |
 |
User Comments (0)
RSS Feeds